BHC supply chain intelligence for Bausch Health Companies Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JPMORGAN-CHASE-BANK-N-A | JPMORGAN-CHASE-BANK-N-A | 92% | the lenders and other persons party thereto, and JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank |
| BAUSCH-LO | BAUSCH-LO | 75% | rebates for Bausch + Lo |
| IRIX | IRIDEX Corporation | 72% | Reciprocal relationship from IRIX graph: Reciprocal relationship from BHC graph: Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such … |
| LNSR | LENSAR, Inc. | 72% | Reciprocal relationship from LNSR graph: Reciprocal relationship from BHC graph: Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from BHC graph: Reciprocal relationship from NKTR graph: the 18 µg/kg rezpegaldesleukin arm, and 11.2% for placebo (p=0.186 and p=0.12… |
| SLGL | Sol-Gel Technologies Ltd. | 72% | Reciprocal relationship from SLGL graph: se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cove… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DURECT-CORPORATION | DURECT-CORPORATION | 85% | e identifiable intangible assets is determined primarily using the “income approach,” which requires a forecast of the expected future cash flows (including revenue growth rates, cost of goods sold, … |
| PAYORS | PAYORS | 85% | We also concentrate on managing our relationships with our payors and wholesalers |
| SHIBO-GROUP | SHIBO-GROUP | 85% | ii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses a… |
| WHOLESALERS | WHOLESALERS | 85% | We also concentrate on managing our relationships with our payors and wholesalers |
| WUHAN-SHIBO-ZHENMEI-TECHNOLOGY-CO-LTD | WUHAN-SHIBO-ZHENMEI-TECHNOLOGY-CO-LTD | 85% | ii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. The commitment periods under these agreements vary and include customary termination provisions. Expenses a… |
| IRIX | IRIDEX Corporation | 72% | Reciprocal relationship from IRIX graph: ete by providing features and services that are valued by our customers such as: enhanced product performance and clinical outcomes, ease of use, durability, … |
| LNSR | LENSAR, Inc. | 72% | Reciprocal relationship from LNSR graph: zation efforts will provide us with significant opportunity for future growth as we continue to penetrate existing and new markets. Our ALLY System currently … |
| MNPR | Monopar Therapeutics Inc. | 72% | Reciprocal relationship from MNPR graph: Reciprocal relationship from BHC graph: Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Ma… |
| SLGL | Sol-Gel Technologies Ltd. | 72% | Reciprocal relationship from SLGL graph: se. We have four registered trademarks in Europe (including United Kingdom), Canada, the United States, Australia, Mexico and Israel. These registrations cove… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: Reciprocal relationship from BHC graph: Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that… |
| XENE | Xenon Pharmaceuticals Inc. | 72% | Reciprocal relationship from XENE graph: Reciprocal relationship from BHC graph: Reciprocal relationship from XENE graph: Reciprocal relationship from BHC graph: Reciprocal relationship from XENE gra… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| BHC-DEBT | Debt stack $20.8B | 90% | Market cache reports total debt of $20.8B. |
| BHC-DEBT-8180 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2012-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| BHC-OWNER-PAULSON-CO-INC | PAULSON & CO. INC. | 90% | 13F overlay lists PAULSON & CO. INC. as top holder; 232 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| LNSR | LENSAR, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| EW | Edwards Lifesciences Corporation | 100.00 | 2 | |
| BRX | Brixmor Property Group Inc. | 100.00 | 2 | |
| BAX | Baxter International Inc. | 100.00 | 2 | |
| TKPHF | Takeda Pharmaceutical Company Limited | 100.00 | 2 | |
| BLCO | Bausch + Lomb Corporation | 100.00 | 1 | ['receiving'] |
| ACRS | Aclaris Therapeutics, Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| WFCF | Where Food Comes From, Inc. | 100.00 | 2 | |
| COO | The Cooper Companies, Inc. | 100.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| IRIX | IRIDEX Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| DNTH | Dianthus Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| COKE | Coca-Cola Consolidated, Inc. | 100.00 | 2 | |
| VITL | Vital Farms, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| NUVB | Nuvation Bio Inc. | 100.00 | 2 |